Stocks Health care COGT
NASDAQ · Health careCogent Biosciences, Inc. (COGT)
It posted a net loss of $407.7M. In fiscal 2025 capital spending exceeded operating cash flow by $266M. At September 30, 2026 it held $217.5M in cash against $223.7M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 5, 2026.
Key facts about Cogent Biosciences, Inc.
- Net worth
- Cogent Biosciences, Inc. has a market value (market cap) of $5.8B at the latest share price, and shareholders' equity of $516.3M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2020 revenue was $7.9M (-65.0% year on year), with a net loss of $74.8M.
- Cash flow
- In fiscal 2025 operations used $264.4M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 5, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Cogent Biosciences, Inc.'s next report is expected around February 16, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Cogent Biosciences, Inc. does
Cogent Biosciences, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker COGT.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$328.9M | -$2.16 | -$266M |
| 2024 | n/a | -$255.9M | -$1.94 | -$208.4M |
| 2023 | n/a | -$192.4M | -$1.94 | -$156.4M |
| 2022 | n/a | -$140.2M | -$1.73 | -$125.5M |
| 2021 | n/a | -$72.3M | -$1.35 | -$60.5M |
| 2020 | $7.9M | -$74.8M | -$11.70 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Cogent Biosciences, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026
- November 5, 2026
- September 2, 2026
- August 13, 2026Passive stake changed SCHEDULE 13G/A
- August 10, 2026Other event 8-K
- August 10, 2026
- August 10, 2026
- July 31, 2026Passive stake (5% or more) SCHEDULE 13G
- July 27, 2026Passive stake changed SCHEDULE 13G/A
- June 11, 2026
Insider trades
What the people running Cogent Biosciences, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $1.7M worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 27, 2026 | Morris ArleneDirector | Exercised options | 41,927 | $236.5K |
| August 27, 2026 | Morris ArleneDirector | Exercised options | 3,583 | $9K |
| August 27, 2026 | Morris ArleneDirector | Soldpre-planned (10b5-1) | 42,349 | $1.6M |
| August 27, 2026 | Morris ArleneDirector | Soldpre-planned (10b5-1) | 3,161 | $118.7K |
| May 19, 2026 | Robbins Andrew RPresident and CEO, Director | Gave as a gift | 160,000 | - |
| May 19, 2026 | Robbins Andrew RPresident and CEO, Director | Gave as a giftindirect | 160,000 | - |
| March 31, 2026 | Fairmount Funds Management LLCDirector | Exercised optionsindirect | 7,000,000 | - |
| March 31, 2026 | Fairmount Funds Management LLCDirector | Soldindirect | 7,000,000 | $242.6M |
Who owns COGT
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Fmr LLC13G, passive with 1 related filers | 15% | February 12, 2025 |
| Fairmount Healthcare Fund II GP LLC13D, may seek influence with 2 related filers | 9.9% | March 27, 2024 |
| Fairmount Funds Management LLC13D, may seek influence with 1 related filers | 8.6% | March 31, 2026 |
| Vanguard Capital Management13G, passive | 5.08% | July 31, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 323 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Fmr LLC | 25,681,174 | +2,558,426 |
| BlackRock, Inc. | 17,352,646 | +1,307,632 |
| Vanguard Portfolio Management LLC | 8,072,411 | +739,078 |
| Vanguard Capital Management LLC | 7,412,330 | +517,371 |
| State Street Corp | 6,964,919 | +1,301,376 |
| Jupiter Topco LLC | 6,624,848 | new |
| Fairmount Funds Management LLC | 5,503,418 | 0 |
| Deerfield Management Company, L.P. | 5,006,104 | -4,037,799 |
| TCG Crossover Management, LLC | 4,854,436 | -92,458 |
| Geode Capital Management, LLC | 4,508,998 | +809,479 |
| Wellington Management Group Llp | 4,343,977 | +765,355 |
| Kynam Capital Management, LP | 3,667,097 | -370,234 |
| Polar Capital Holdings Plc | 3,232,905 | new |
| Commodore Capital LP | 3,050,000 | +161,993 |
| Assenagon Asset Management S.A. | 2,883,512 | +2,587,862 |
| Invesco Ltd. | 2,609,141 | +179,512 |
| Woodline Partners LP | 2,603,162 | +1,093,605 |
| Pictet Asset Management Holding SA | 2,393,515 | +594,747 |
| Octagon Capital Advisors LP | 2,350,000 | 0 |
| Rtw Investments, LP | 2,309,021 | -3,149,654 |
Insiders
7 insiders reported holding 6,892,743 shares in total, about $231.2M at the last price.
| Holder | Shares |
|---|---|
| Fairmount Funds Management LLCDirector | 5,503,4185,503,418 held indirectly |
| Robbins Andrew RPresident and CEO, Director | 657,503160,000 held indirectly |
| Pinnow ColeChief Commercial Officer | 216,650 |
| Robinson John EdwardChief Scientific Officer | 140,002 |
| Sachs JessicaChief Medical Officer | 133,938 |
| Green John L.Chief Financial Officer | 131,834 |
| Kearns EvanChief Legal Officer | 109,398 |
Questions about COGT
What does Cogent Biosciences, Inc. do?
Cogent Biosciences, Inc. is a company in the Health care sector, listed on NASDAQ as COGT. Its shares trade on NASDAQ under the ticker COGT.
What is Cogent Biosciences, Inc.'s net worth?
Cogent Biosciences, Inc. has a market value (market cap) of $5.8B at the latest share price, and shareholders' equity of $516.3M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Cogent Biosciences, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $407.7M.
When did Cogent Biosciences, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 5, 2026. It covers the period to September 30, 2026.
When is Cogent Biosciences, Inc.'s next earnings report?
Cogent Biosciences, Inc.'s next report is expected around February 16, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare COGT with
Follow COGT
Get an email when Cogent Biosciences, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Cogent Biosciences, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.